
Cemiplimab's proposed EU regimen could cut Libtayo infusion visits from every 3 weeks to every 6 weeks, trimming infusion time by up to half.
Spectrum Pharmaceuticals appoints Joseph Turgeon as president and COO.
Turgeon joined Spectrum in October 2012 and has over 30 years of pharmaceutical sales experience. Prior to joining the Spectrum, hespent 22 years at Amgen as VP of sales. Riga has over 15 years of pharmaceutical sales and management experience and has worked at Amgen, EliLilly, and Dendreon.
Source: